

The Scottish Pregnancy Intervention Study: The effect of low molecular weight heparin and aspirin therapy on recurrent pregnancy loss

Submission date 23/08/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/09/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 07/04/2010	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Peter Clark

Contact details
Scottish National Blood
Transfusion Service
East of Scotland Blood Transfusion Centre
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY

Additional identifiers

Protocol serial number
OBGYN_SPIN_01

Study information

Scientific Title

Acronym

SPIN

Study objectives

Does treatment with low dose aspirin and Low Molecular Weight Heparin (LMWH) in women with consecutive recurrent pregnancy loss(es) at less than/equal to 24 weeks gestation (and no evidence of anatomical, endocrine, chromosomal or immunological abnormality) result in a reduction in the rate of expected loss in the index pregnancy from 25% to 15% or less?

Please note that as of 13/11/2007 the funding by the Chief Scientist Office was extended from 31/05/2007 to the 31/12/2008 for this trial. The end date of this trial has been changed to reflect this.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the North West Multicentre Research Ethics Committee (MREC) on the 30th September 2003 (ref: MREC 03/8/041)

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Recurrent miscarriage

Interventions

Low Molecular Weight Heparin, aspirin and intense surveillance versus intense surveillance only.

Medications given as follows: enoxaparin 40 mg subcutaneously, once per day by self injection and 75 mg aspirin orally once daily. Medications are prescribed at randomisation and stop at 36 weeks gestation.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Aspirin, low molecular weight heparin (LMWH)

Primary outcome(s)

Live birth rate (delivery of a live infant beyond 37 weeks of gestation).

Key secondary outcome(s)

1. Preterm delivery of a live infant (between 28 and 37 weeks of gestation)
2. Obstetric complications (pregnancy associated hypertension, pre-eclampsia, intrauterine growth retardation)
3. Congenital malformations
4. Admission to special care
5. Side-effects of the drug used, both for the mother and the baby
6. Thromboembolic complications

Completion date

31/12/2008

Eligibility**Key inclusion criteria**

1. Have a history of a minimum of two consecutive early pregnancy losses (defined as at/or before 24 weeks gestation)
2. Present at less than or equal to 7 weeks gestation with a positive pregnancy test and confirmatory ultrasound
3. Give written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. A previous foetal loss has been associated with an anatomical, chromosomal,(maternal /paternal) endocrine or immunological cause
2. They have a previous history of venous or arterial thrombosis
3. They are already known to have antiphospholipid syndrome (as defined by the presence of an antiphospholipid antibody and three consecutive early pregnancy failures)
4. At enrolment are already known to have a thrombophilic disorder
5. They have a history of three or more pregnancy losses and are found or are already known to have a positive lupus inhibitor screen or Immunoglobulin G (IgG)/Immunoglobulin M (IgM) anticardiolipin antibodies above the local reference range
6. Are found to have an excluding condition on booking for the current pregnancy such as anaemia requiring therapy, platelets less than $150 \times 10^{12}/l$, abnormal thyroid function, multiple or rare red cell alloantibodies or auto-antibodies
7. Known hypersensitivity to the active substance or any of the excipients

Date of first enrolment

01/06/2004

Date of final enrolment

31/12/2008

Locations

Countries of recruitment

United Kingdom

Scotland

Study participating centre**Scottish National Blood**

Dundee

United Kingdom

DD1 9SY

Sponsor information

Organisation

Greater Glasgow Health Board (North Glasgow University Hospitals Division) and Glasgow University (UK)

ROR

<https://ror.org/05kdz4d87>

Funder(s)

Funder type

Government

Funder Name

Scottish Executive, Health Department, Chief Scientist Office (UK) (Ref: CZB/4/110)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type

[Results article](#)

Details
results

Date created

27/05/2010

Date added

Peer reviewed?

Yes

Patient-facing?

No